Kamada Ltd. (TLV:KMDA)
Israel · Delayed Price · Currency is ILS · Price in ILA 2,243.00
-21.00 (-0.93%)
At close: Dec 25, 2025
Kamada Employees
Kamada had 420 employees as of December 31, 2024. The number of employees increased by 42 or 11.11% compared to the previous year.
Employees
420
Change (1Y)
42
Growth (1Y)
11.11%
Revenue / Employee
1.38M ILS
Profits / Employee
161.17K ILS
Market Cap
1.29B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 420 | 42 | 11.11% |
| Dec 31, 2023 | 378 | -2 | -0.53% |
| Dec 31, 2022 | 380 | 25 | 7.04% |
| Dec 31, 2021 | 355 | -53 | -12.99% |
| Dec 31, 2020 | 408 | -21 | -4.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 35,686 |
| Danel (Adir Yeoshua) | 4,290 |
| Novolog (Pharm-Up 1966) | 936 |
| InterCure | 320 |
| Bait Bakfar | 227 |
| Ilex Medical | 178 |
| SofWave Medical | 126 |
| BrainsWay | 120 |
Kamada News
- 9 days ago - Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender - GlobeNewsWire
- 18 days ago - Kamada Ltd Corporate Update Call Transcript - GuruFocus
- 19 days ago - Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook - Benzinga
- 19 days ago - Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook - Benzinga
- 19 days ago - Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript - Seeking Alpha
- 19 days ago - Kamada (KMDA) Halts Phase 3 Trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency - GuruFocus
- 6 weeks ago - Kamada (KMDA) is an Incredible Growth Stock: 3 Reasons Why - Nasdaq
- 6 weeks ago - Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - GuruFocus